The results of recent large cohort trials in combination with the inherent properties of 177Lu-PSMA-617 have led to its current exploration as a promising treatment modality beyond progressive metastatic CRPC (mCRPC), and into the earlier phases of prostate cancer treatment. The gene discussed is FOLH1; the disease is prostate carcinoma.